Assessment of endpoints for clinical trials for localized prostate cancer

Urology

Volumn 49, Issue 4 SUPPL., 1997, Pages 27-38

  Schellhammer, Paul ^a,i   Cockett, Abraham ^b   Boccon Gibod, Laurent ^c   Gospodarowicz, Mary ^j   Krongrad, Arnon ^d,e   Thompson, Ian Murchie ^f   Scardino, Peter ^g   Soloway, Mark ^d   Adolfsson, Jan ^h  

^a Sentara Cancer Resource Centers   (United States)

^b UNIVERSITY OF ROCHESTER SCHOOL OF MEDICINE AND DENTISTRY   (United States)

^c BICHAT HOSPITAL   (France)

^d UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^e VETERANS AFFAIRS MEDICAL CENTER   (United States)

^f BROOKE ARMY MEDICAL CENTER   (United States)

^g BAYLOR COLLEGE OF MEDICINE   (United States)

^h KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

ⁱ River Pavilion   (United States)

^j NONE

more..

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; CANCER LOCALIZATION; HUMAN; PRIORITY JOURNAL; PROSTATE CANCER; QUALITY OF LIFE; TREATMENT PLANNING;

EID: 0030905231     PISSN: 00904295     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0090-4295(99)80321-5     Document Type: Article

References (78)

1. Parker SL, Tong T, Bolden S, and Wingo PA: Cancer statistics, 1996. CA Cancer J Clin 46: 5-7, 1996.
2. Yancik R, and Ries LA: Cancer in older persons: magnitude of the problem - how do we apply what we know? Cancer 74: 1995-2003, 1994.
3. Lubitz J, Beebe J, and Baker C: Longevity and Medicare expenditures. New Eng J Med 332: 999-1003, 1995.
4. Manton KG, Wrigley MJ, Cohen HJ, and Woodbury MA: Cancer mortality, aging, and patterns of comorbidity in the United States: 1968 to 1986. J Gerontol 46: S225-S234, 1991.
5. Boyle P, Maisonneuve P, and Napalkov P: Geographical and temporal patterns of incidence and mortality from prostate cancer. Urology 46: 47-55, 1995.
6. Schmidt JD, Mettlin CJ, Natarajan N, Peace BB, Beart JRW, Winchester DP, and Murphy GP. Trends in patterns of care for prostatic cancer, 1974-1983: results of surveys by the American College of Surgeons. J Urol 136: 416-421, 1986.
7. Lu-Yao GL and Greenberg ER: Changes in prostate cancer incidence and treatment in USA. Lancet 343: 251-254, 1994.
8. Lu-Yao GL, McLerran D, Wasson J, and Wennberg JE, for the Prostate Patient Outcomes Research Team. An assessment of radical prostatectomy: time trends, geographic variation, and outcomes. JAMA 269: 2633-2636, 1993.
9. Fleming C, Wasson JH, Albertsen PC, Barry MJ, and Wennberg JE: A decision analysis of alternative treatment strategies for clinically localized prostate cancer. JAMA 269: 2650, 1993.
10. Adolfsson J, Steineck G, and Whitmore WF Jr.: Recent results of management of palpable clinically localized prostate cancer. Cancer 72: 310-322, 1993.
11. Middleton RG, Thompson IM, Austenfeld MS, et al.: Prostate Cancer Clinical Guidelines Panel Summary report on the management of clinically localized prostate cancer. The American Urological Association. J Urol 154: 2144-2148, 1995.
12. Krongrad A, Lai H, Lamm SH, and Lai S: Mortality in prostate cancer. J Urol 156: 1084-1091, 1996.
13. Paulson DF, Lin GH, Hinshaw W, et al: Radical surgery versus radiotherapy for adenocarcinoma of the prostate. J Urol 128: 502-504, 1982.
14. Iverson P, Madsen P, and Corle D: Radical prostatectomy vs. expectant treatment for early carcinoma of the prostate. Twenty-three year follow-up of a prospective randomized study. ScandJ Urol Nephrol 172: 65-72, 1995.
15. Wasson JH, Cushman CC, Bruskewitz RC, Littenberg B, Mulley AG, and Wennberg JE: A structured literature review of treatment for localized prostate cancer. Arch Fam Med 2: 487-493, 1993.
16. Albertsen PC, Fryback DG, Storer BE, Kolon TF, and Fine J: Long-term survival among men with conservatively treated localized prostate cancer. JAMA 274: 626, 1995.
17. Prentice RL: Surrogate endpoints in clinical trials: definition and operational criteria. Stat Med 8: 431-440, 1989.
18. Cox DR: Regression models and life tables. J Roy Stat Soc 34: 187-220, 1972.
19. Ellenberg SS and Hamilton JM: Surrogate endpoints in clinical trials: cancer. Stat Med 8: 405-413, 1989.
20. Fleming TR: Surrogate markers in AIDS and cancer trials. Stat Med 13: 1423-1435, 1994.
21. The Cardiac Arrhythmia Suppression Trial (CAST) Investigators, Preliminary report: effect of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction. N Engl J Med 321: 406-412, 1989.
22. SWOG-9450. "Prostate Cancer Intervention Versus Observation Trial" (PIVOT): CSP #407.
23. Peto R, Collins R, and Gray R: Large-scale randomized evidence: large, simple trials and overviews of trials. J Clin Epidemiol 48: 23-40, 1995.
24. Begg C, Cho M, Eastwood S, Horton R, Moher D, Olkin I, Pitkin R, Rennie D, Schulz K, Simel D, and Stroup D: Improving the quality of reporting of randomized controlled trials. JAMA 276(8): 637-639, 1996.
25. Clark J, Lillis P, O'Rourke T, Jones C, Higgins B, and Thompson IM: Reliability of disease specific survival in prostate cancer trials. J Urol 153: 252A, 1995.
26. Brown BW, Brauner C, and Minnotte MC: Noncancer deaths in white adult cancer patients. J Natl Cancer Inst 85: 979, 1993.
27. Byar DP, Anderson J, Blumenstein B, Gibbons RP, Lepor H, Olsson CA, and Simon R: Guidelines for reporting studies of treatment for prostatic cancer. A multidisciplinary analysis of controversies in the management of prostate cancer. Prout's Neck Conference on prostate cancer (2nd, 1986).
28. Steineck G, Adolfsson J, and Whitmore WFJr.: "Local Recurrence" and "Disease-free Survival" - Doubtful parameters when comparing non-randomized studies of prostate cancer: Scand J Urol Nephrol Suppl 138: 121-126, 1991.
29. Moinpour CM, Seigl P, Metch B, Hayden KA, Meyskens FL Jr., and Crowley J: Quality of life endpoints in cancer clinical trials: review and recommendation. JNCI 81(7): 485-495, 1989.
30. Angulo JC, Montie JE, Bukowsky T, Charkrabarty A, Grignon DJ, Sakr W, Shamsa FH, and Pontes JE: Interobserver consistency of digital rectal examination in clinical staging of localized prostatic carcinoma. Urol Oncol 1: 199-205, 1995.
31. Smith DS, and Catalona WJ: Interexaminer variability of digital rectal examination in detecting prostate cancer. Urol 45: 70-74, 1995.
32. Thompson IM, Ernst JJ, Gangai MP, et al: Adenocarcinoma of the prostate: Results of routine urological screening. J Urol 132: 690, 1984.
33. Chodak GW, Keller P, and Schoenberg HW: Assessment of screening for prostate cancer using the digital rectal examination. J Urol 141: 1136, 1989.
34. Terris MK, Freiha FS, McNeal JE, and Stamey TA: Efficacy of transrectal ultrasound for identification of clinically undetected prostate cancer. J Urol 146: 78-84, 1991.
35. Flanigan RC, Catalona WJ, Richie JP, Ahmann FR, Hudson MA, Scardino PT, deKernion JB, Ratliff TL, Kavoussi LR, Dalkin BL, Waters WB, McFarlane MT, and Southwick PC: Accuracy of digital rectal examination and transrectal ultrasonography in localizing prostate cancer. J Urol 152: 1506-1509, 1994.
36. Keetch DW, and Andriole GL: Prostate Cancer Screening: What are physicians to do? What have we learned? 1996 Monographs in Urology 17: 31-48.
37. Kabalin JN, Hodge KK, McNeal JE, Freiha FS, and Stamey TA: Identification of residual cancer in the prostate following radiation therapy: role of transrectal ultrasound-guided biopsy and prostate specific antigen. J Urol 142: 326-331, 1989.
38. Schellhammer PF and El-Mahdi AM: Local failure and related complications after definitive treatment of carcinoma of the prostate by irradiation or surgery. Urol Clin North Am 17: 835-851, 1990.
39. Zietman AL, Shipley WU, and Willett CG: Residual disease after radical surgery or radiation therapy for prostate cancer. Clinical significance and therapeutic implications. Cancer 71: 959-969, 1993.
40. Miller EB, Ladaga LE, El-Mahdi AM, and Schellhammer PE: Reevaluation of prostate biopsy after definitive radiation therapy. Urology 41: 311-316, 1993.
41. Ferguson JK, and Oesterling JE: Patient evaluation if prostate specific antigen becomes elevated following radical prostatectomy or radiation therapy. Urol Clin North Am 21: 677-685, 1994.
42. Babaian EJ, Kojima M, Saitoh M, and Ayala AG: Detection of residual prostate cancer after external radiotherapy. Role of prostate specific antigen and transrectal ultrasonography. Cancer 75: 2153-2158, 1995.
43. Goldenberg SL, Carter M, Dashefsky S, and Cooperberg PL: Sonographic characteristics of the urethrovesical anastomosis in the early post-radical prostatectomy patient. J Urol 152: 1506-1509, 1994.
44. Abi-Aad AS, Macfarlane MT, Stein A, and deKernion JB: Detection of local recurrence after radical prostatectomy by prostate specific antigen and transrectal ultrasound. J Urol 147: 952-955, 1992.
45. Wasserman NF, Kappor DA, and Hildebrandts WC, et al.: Transrectal ultrasound in evaluation of patients after radical prostatectomy. Part I normal postoperative anatomy. Radiology 185: 361-366, 1992.
46. Connolly JA, Shinohara K, Presti JC, and Carroll PR: Local recurrence after radical prostatectomy characteristics in size, location, and relationship to prostate specific antigen and surgical margins. Urology 47: 225-231, 1996.
47. Foster LS, Jagodia P, Fournier G, Shinohave K, Carrole P, and Marayan P: The value of PSA and TRUS guided biopsy in detecting prostatic fossa recurrences following radical prostatectomy. J Urol 149: 1024, 1993.
48. Egawa S, Wheeler TM, Greene DR, and Scardino PT: Detection of residual prostate cancer after radiotherapy by sonographically guided needle biopsy. Urology 39: 358-363, 1992.
49. Stamey TA, Ferrari MK, and Schmid HP: The value of serial PSA determination 5 years after radiotherapy, steeply increasing values characterize 80% of patients. J Urol 150: 1856, 1993.
50. Kabalin JN: Prostate needle biopsy following radiotherapy for prostate cancer (letter). Urology 46: 603, 1995.
51. Forman JD, Oppenheim T, Liu H, Montie J, McLaughlin PW, and Porter AT: Frequency of residual neoplasm in the prostate following three dimensional conformal radiotherapy. The Prostate 23: 235-243, 1993.
52. Crook J, Perry G, Robertson S, and Esche B: Radiotherapy for localized prostate cancer: assessment of results by systematic biopsy and PSA. Canadian Journal of Urology 3(1), 46, 1996.
53. Svetec D, McCabe K, Peretsman S, Klein E, Levin H, and Thompson I. Prostatic biopsy is a poor surrogate for treatment efficacy in localized prostate cancer. Proceedings of the 1996 Vale, Colorado, September '96 South Central Section Annual Meeting.
54. Bostwick DG, Egbert BM, and Fajardo LF: Radiation injury of the normal and neoplastic prostate. AmJ Surg Pathol 6: 541-551, 1982.
55. Soloway MS, Hardeman SW, Hickey D, Raymond J, Todd B, Soloway S, and Moinuddin M: Cancer 61: 195-202, 1988.
56. Flanigan RC, McKay TC, Olson M, Shankey TV, Pyle J, and Waters WB: Limited efficacy of preoperative computed tomographic scanning for the evaluation of lymph node metastasis in patients before radical prostatectomy. Urology 48: 428-452, 1996.
57. Konety BR, Naraghi R, Gooding W, O'Donnell WF, and Bahnson RR: Evaluation of computerized tomography for staging of clinically localized adenocarcinoma of the prostate. Urol Oncol 2: 14-19, 1996.
58. Kahn D, Williams RD, Seldin DW, Libertino JA, Hirschhorn M, Dreicer R, Weiner GJ, Bushnell D, and Gulfo J: Radioimmunoscintigraphy with 111indium-labeled CYT-356 for the detection of occult prostate cancer recurrence. J Urol 152: 1490-1495, 1994.
59. Epstein JI, Pizov G, and Walsh PC: Correlation of pathologic findings with progression after radical retropubic prostatectomy. Cancer 71: 3582-3593, 1993.
60. Stein A, deKernion JB, Smith RB, Dorey F, and Patel H: Prostate specific antigen levels after radical prostatectomy in patients with organ confined and locally extensive prostate cancer. J Urol 147: 942-946, 1992.
61. Catalona WJ, and Smith DS: 5-year tumor recurrence rates after anatomical radical retropubic prostatectomy for prostate cancer. J Urol 152: 1837-1842, 1994.
62. Partin AW, Lee BR, Carmichael M, Walsh PC, and Epstein JI: Radical prostatectomy for high grade disease: a reevaluation 1994. J Urol 151: 1583-1586, 1994.
63. Oefelein, MG, Smith N, Carter M, Dalton D, and Schaeffer A: The incidence of prostate cancer progression with undetectable serum prostate specific antigen in a series of 394 radical prostatectomies. J Urol 154: 2128-2131, 1995.
64. Dillioglugil O, Leibman BD, Wheeler TM, and Scardino PT: Distant metastasis after radical prostatectomy in patients without an elevated serum prostate specific antigen level. Cancer 76(12): 2530-2534, 1995.
65. Critz FA, Tarlton RS, and Holladay DA: Prostate specific antigen monitored combination radiotherapy for patients with prostate cancer. Cancer 75: 2383-2391, 1995.
66. Kavadi V, Zagars G, and Pollack A: Serum prostate-specific antigen after radiation therapy for clinically localized prostate cancer: Prognostic implications. Int J Radiat Oncol Biol Phys 30(2): 270, 1994.
67. Tibbs M, Zeitman A, Dallow KC, et al: Biochemical outcome following external beam radiation for T1-2 prostate carcinoma: the importance of achieving an undetectable nadir PSA. Int J Radiat Oncol Biol Phys 32(1): 230, 1995.
68. Partin AW, Pound CR, Clemens JQ, Epstein JI, and Walsh PC: Serum PSA after anatomic Radical Prostatectomy. Urol Clin North Am 20: 713, 1993.
69. Willett CG, Zietman AL, Shipley WU, and Coen JJ: The effect of pelvic radiation therapy on serum levels of prostate specific antigen. J Urol 151: 1579-1581, 1994.
70. 70: Grob BM, Schellhammer PF, Brassil DN, and Wright GL Jr.: Changes in immunohistochemical staining of PSA, PAP, and TURP-27 following irradiation therapy for clinically localized prostate cancer. Urology 44: 525-529, 1994.
71. Zagars GK, Pollack A, Kavadi VS, and von Eschenbach AC: Prostate-specific antigen and radiation therapy for clinically localized prostate cancer. Int J Radiat Oncol Biol Phys 32: 293-306, 1995.
72. Zelefsky MJ, Leibel SA, Wallner KE, Whitmore W Jr, and Fuks Z: Significance of normal serum prostate-specific antigen in the follow-up period after definitive radiation therapy for prostatic cancer. J Clin Oncol 13: 459-463, 1995.
73. Zietman A, Tibbs M, Dallow K, Smith C, Althausen A, Zlotecki RA, and Shipley W: The use of PSA nadir to predict subsequent biochemical outcome following external beam radiation therapy for T1-2 adenocarcinoma of the prostate. Radiother Oncol 40: 159-162, 1996.
74. Critz F, Levinson A, Williams H, and Holladay D: PSA nadir: The optimum level after irradiation for prostate cancer. J Clin Oncol 14: 2893-2900, 1996.
75. Catalona WJ, Smith DS, and Wolfert RL, et al: Evaluation of percentage of free serum prostate specific antigen to improve specificity of prostate cancer screening. JAMA 274: 1214-1220, 1995.
76. Thalmann GN, Sikes RA, Chang SM, Johnston DA, von Eschenbach AC, and Chung LWK: Suramin-induced decrease in prostate-specific antigen expression with no effect on tumor growth in the LNCaP model of human prostate cancer. J Natl Cancer Insti 88: 794-801, 1996.
77. Seckin B, Anthony CT, Murphy B, and Steiner MS: Can prostate-specific antigen be used as a valid end point to determine the efficacy of chemotherapy for advanced prostate cancer? World J Urol 14: S26-S29, 1996.
78. Eisenberger MA, and Nelson WG: How much can we rely on the level of prostate-specific antigen as an endpoint for evaluation of clinical trials? A word of caution! JNCI 88(12), June 1996.